title: Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
abstract: Lenalidomide has been approved by the US Food and Drug Administration for the treatment of patients with myelodysplastic syndromes (MDS) with an interstitial deletion of the long arm of chromosome 5 and, more recently, in combination with dexamethasone for multiple myeloma in patients who received at least one prior therapy. This discussion examines several clinically relevant, practical considerations regarding dosing, monitoring, follow-up evaluation, adverse events, and available support for lenalidomide recipients and their prescribing physicians in the MDS setting.
authors.affiliation: University of Arizona, Arizona Cancer Center, Tucson, 85724, USA. skurtin@umcaz.edu
authors.forename: Sandra
authors.initials: S
authors.lastname: Kurtin
authors.forename: Lubomir
authors.initials: L
authors.lastname: Sokol
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000235:genetics; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D000077269:Lenalidomide; D008495:Medical Oncology / Q000639:trends; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide